SAA (Serum Amyloid A): A Novel Predictor of Stroke-Associated Infections.
Aged
Aged, 80 and over
Area Under Curve
Biomarkers
C-Reactive Protein
/ metabolism
Clinical Decision Rules
Cross Infection
/ epidemiology
Deglutition Disorders
/ physiopathology
Female
Healthcare-Associated Pneumonia
/ epidemiology
Humans
Ischemic Stroke
/ metabolism
Leukocyte Count
Logistic Models
Male
Middle Aged
Procalcitonin
/ metabolism
ROC Curve
Reproducibility of Results
Sepsis
/ metabolism
Serum Amyloid A Protein
/ metabolism
Urinary Tract Infections
/ metabolism
ROC curve
biomarkers
cohort studies
infections
serum amyloid A protein
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
10
11
2020
medline:
18
2
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate and independently validate SAA (serum amyloid A)-a recently discovered blood biomarker-to predict poststroke infections. The derivation cohort (A) was composed of 283 acute ischemic stroke patients and the independent validation cohort (B), of 367 patients. The primary outcome measure was any stroke-associated infection, defined by the criteria of the US Centers for Disease Control and Prevention, occurring during hospitalization. To determine the association of SAA levels on admission with the development of infections, logistic regression models were calculated. The discriminatory ability of SAA was assessed, by calculating the area under the receiver operating characteristic curve. After adjusting for all predictors that were significantly associated with any infection in the univariate analysis, SAA remained an independent predictor in study A (adjusted odds ratio, 1.44 [95% CI, 1.16-1.79]; Among patients with ischemic stroke, blood SAA measured on admission is a novel independent predictor of infection after stroke. SAA improved the discrimination between patients who developed an infection compared with those who did not in both derivation and validation cohorts. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00390962.
Sections du résumé
BACKGROUND AND PURPOSE
The aim of this study was to evaluate and independently validate SAA (serum amyloid A)-a recently discovered blood biomarker-to predict poststroke infections.
METHODS
The derivation cohort (A) was composed of 283 acute ischemic stroke patients and the independent validation cohort (B), of 367 patients. The primary outcome measure was any stroke-associated infection, defined by the criteria of the US Centers for Disease Control and Prevention, occurring during hospitalization. To determine the association of SAA levels on admission with the development of infections, logistic regression models were calculated. The discriminatory ability of SAA was assessed, by calculating the area under the receiver operating characteristic curve.
RESULTS
After adjusting for all predictors that were significantly associated with any infection in the univariate analysis, SAA remained an independent predictor in study A (adjusted odds ratio, 1.44 [95% CI, 1.16-1.79];
CONCLUSIONS
Among patients with ischemic stroke, blood SAA measured on admission is a novel independent predictor of infection after stroke. SAA improved the discrimination between patients who developed an infection compared with those who did not in both derivation and validation cohorts. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00390962.
Identifiants
pubmed: 33161846
doi: 10.1161/STROKEAHA.120.030064
doi:
Substances chimiques
Biomarkers
0
Procalcitonin
0
Serum Amyloid A Protein
0
C-Reactive Protein
9007-41-4
Banques de données
ClinicalTrials.gov
['NCT00390962']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM